Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL28217737 | 1.00 | KDM4E (0.53) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL526776 | 1.00 | — | — | |
| Sulfuric Acid SCHEMBL27434030 | 0.90 | KDM4E (0.52) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| Thiourea SCHEMBL933625 | 0.86 | — | — | |
| Sulfuric Acid SCHEMBL28148838 | 0.84 | BLM (0.59) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| Sulfuric Acid SCHEMBL170524 | 0.84 | — | — | |
| Sulfuric Acid SCHEMBL1318239 | 0.84 | BLM (0.59) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| Thiourea SCHEMBL28009945 | 0.83 | KDM4E (0.46) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| Thiourea SCHEMBL28217736 | 0.81 | KDM4E (0.38) | KDM4EBLMCYP2D6CYP2C19NPSR1 | |
| Thiourea SCHEMBL8576993 | 0.81 | BLM (0.43) | KDM4EBLMCYP2D6CYP2C19NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115636773-B | Aryl ester compound containing guanylurea or guanylester, and preparation and application thereof | 中国农业大学 | 2023-11-17 | — | — | CN | claimed |
| CN-116444421-A | Arylpiperidine compound containing guanidyl urea and preparation and application thereof | 中国农业大学 | 2023-07-18 | — | — | CN | claimed |
| CN-115636773-B | Aryl ester compound containing guanylurea or guanylester, and preparation and application thereof | 中国农业大学 | 2023-11-17 | — | — | CN | disclosed |
| CN-116444421-A | Arylpiperidine compound containing guanidyl urea and preparation and application thereof | 中国农业大学 | 2023-07-18 | — | — | CN | disclosed |
| CN-114555586-B | KRASG12C protein inhibitor and preparation method and application thereof | 信达生物制药(苏州)有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115636773-A | Aryl ester compound containing guanidinyl urea or guanidinyl ester and preparation and application thereof | 中国农业大学 | 2023-01-24 | — | — | CN | disclosed |
| US-9546173-B2 | Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| EP-2897961-B1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| US-20150274733-A1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-10-01 | — | — | US | disclosed |
| CN-100575330-C | Novel compounds | ASTRAZENECA AB | 2009-12-30 | — | — | CN | disclosed |
| WO-2007074391-A2 | PREPARATION OF A KEY INTERMEDIATE IN THE SYNTHESIS OF ROSUVASTATIN | KHAMAR BAKULESH MAFATLAL (IN) | 2007-07-05 | — | — | WO | disclosed |
| US-4025527-A | H-2 HISTAMINE RECEPTOR INHIBITORS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-24 | — | — | US | disclosed |
| US-4022797-A | PHARMACEUTICALS | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1977-05-10 | — | — | US | disclosed |
| US-4005202-A | 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity | SYNTEX (U.S.A.) INC. (US) | 1977-01-25 | — | — | US | disclosed |
| US-4002640-A | ANTIFUNGAL AGENTS | SYNTEX (U.S.A.) INC. (US) | 1977-01-11 | — | — | US | disclosed |
| US-4000302-A | ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) | 1976-12-28 | — | — | US | disclosed |
| US-3993768-A | FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1976-11-23 | — | — | US | disclosed |
| US-3965113-A | 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity | SYNTEX (U.S.A.) INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3962437-A | 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity | SYNTEX (U.S.A.) INC. (US) | 1976-06-08 | — | — | US | disclosed |
| US-3935209-A | 5(6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity | SYNTEX (U.S.A.) INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274733-A1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | MAP3K1, MAP3K2, BRAF | KDM4E 2333/4885BLM 3905/4885CYP2D6 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.